Allogenica

Allogenica is a biotechnology company that develops a breakthrough cell therapy platform to disrupt the treatment landscape for cancer, rare diseases, and autoimmune disorders. Their unique expertise enables the differentiation of stem cells into immature precursor T cells, and their innovative vector allows these cells to be modified to produce a new generation of allogeneic T-cell therapies. Allogenica aims to make T-cell therapies universally accessible by delivering treatments that are safer, more readily available to patients, and up to ten times less expensive to manufacture.